Pentostatin

Pentostatin

Pentostatin
Systematic (IUPAC) name
(R)-3-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
Clinical data
Trade names Nipent
AHFS/Drugs.com
MedlinePlus
Pregnancy
category
  • US: D (Evidence of risk)
Legal status
Routes of
administration
Intravenous
Pharmacokinetic data
Bioavailability n/a
Protein binding 4%
Metabolism Hepatic, minor
Biological half-life 2.6 to 16 hours, mean 5.7 hours
Identifiers
CAS Registry Number  YesY
ATC code L01
PubChem CID:
IUPHAR/BPS
DrugBank  YesY
ChemSpider  YesY
UNII  YesY
KEGG  YesY
ChEMBL  YesY
Chemical data
Formula C11H16N4O4
Molecular mass
Documentation

 YesY   

Pentostatin (or deoxycoformycin, trade name Nipent, manufactured by SuperGen) is an anticancer chemotherapeutic drug.[1]

Mechanism

It is classified as a purine analog, which is a type of antimetabolite.

It mimics the nucleoside adenosine and thus inhibits the enzyme adenosine deaminase, interfering with the cell's ability to process DNA.[2]

Cancer cells generally divide more often than healthy cells; DNA is highly involved in cell division (mitosis) and drugs which target DNA-related processes are therefore more toxic to cancer cells than healthy cells.

Uses

Pentostatin is used to treat hairy cell leukemia.[3] It is given by intravenous infusion once every two weeks for three to six months.

Additionally, pentostatin has been used to treat steroid-refractory acute and chronic graft-versus-host disease.[4]

Pentostatin is also used in chronic lymphocytic leukemia (CLL) patients who have relapsed.

References

  1. ^
  2. ^
  3. ^
  4. ^